Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays

Thrombosis Research

Volumn 132, Issue 2, 2013, Pages

  Tsantes, Argirios E ^a   Ikonomidis, Ignatios ^a   Papadakis, Ioannis ^a   Bonovas, Stefanos ^b   Gialeraki, Argiri ^a   Kottaridi, Christine ^a   Kyriakou, Elias ^a   Kokori, Styliani ^a   Douramani, Panagiota ^a   Kopterides, Petros ^a   Karakitsos, Petros ^a   Lekakis, John ^a   Kapsimali, Violetta ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clopidogrel resistance; CYP2C19*2; Platelet function assay; polymorphism; Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; OMEPRAZOLE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ALLELE; ARTICLE; DRUG ANTAGONISM; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; UNSTABLE ANGINA PECTORIS;

ACS; ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; AUC; CAD; CLOPIDOGREL RESISTANCE; CLOSURE TIME; CORONARY ARTERY DISEASE; CT; CYP; CYP2C19*2 POLYMORPHISM; CYTOCHROME P450; FLOW-CYTOMETRIC VASODILATOR-STIMULATED PHOSPHOPROTEIN; LIGHT TRANSMITTANCE AGGREGOMETRY; LTA; MEA; MULTIPLE ELECTRODE AGGREGOMETRY; PCI; PERCUTANEOUS CORONARY INTERVENTION; PFA; PLATELET FUNCTION ANALYZER; PLATELET FUNCTION ASSAY; PLATELET REACTIVITY INDEX; PLATELET-POOR PLASMA; PLATELET-RICH PLASMA; PPI; PPP; PRI; PROTON PUMP INHIBITOR; PROTON PUMP INHIBITORS; PRP; REAL-TIME POLYMERASE CHAIN REACTION; RT-PCR; SINGLE-NUCLEOTIDE POLYMORPHISM; SNP; ST-ELEVATION MYOCARDIAL INFARCTION; STEMI; VASP;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 84883782125     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.06.015     Document Type: Article

References (33)

1. G. Davi, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
2. Z.M. Ruggeri Platelets in atherothrombosis Nat Med 8 2002 1227 1234
3. S.R. Steinhubl, P.B. Berger, J.T. Man III on behalf of CREDO Investigators Clopidogrel for the Reduction of Events During Observation. Early and sustained oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
4. Z.M. Chen, L.X. Jiang, Y.P. Chen on behalf of COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo controlled trial Lancet 366 2005 1607 1621
5. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, J.S. Baggish, and D.L. Bhatt Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials Am J Cardiol 95 2005 1218 1222
6. P.A. Gurbel, K.P. Bliden, B.L. Hiatt, and C.M. O'Connor Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity Circulation 107 2003 2908 2913
7. P.A. Gurbel, K.P. Bliden, W. Samara, J.A. Yoho, K. Hayes, and M.Z. Fissha Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study J Am Coll Cardiol 46 2005 1827 1832
8. N.J. Breet, J.W. van Werkum, H.J. Bouman, J.C. Kelder, H.J. Ruven, and E.T. Bal Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
9. D.J. Kereiakes, and P.A. Gurbel Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention J Am Coll Cardiol Intv 1 2008 111 121
10. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
11. A.R. Shuldiner, J.R. O'Connell, K.P. Bliden, A. Gandhi, K. Ryan, and R.B. Horenstein Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
12. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Méneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
13. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
14. M.V. Holmes, P. Perel, T. Shah, A.D. Hingorani, and J.P. Casas CYP2C19 Genotype, clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis JAMA 306 2011 2704 2714
15. J.M. Siller-Matula, I. Lang, G. Christ, and B. Jilma Calcium-channel blockers reduce the antiplatelet effect of clopidogrel Am Coll Cardiol 52 2008 1557 1563
16. N.A. Farid, D.S. Small, C.D. Payne, J.A. Jakubowski, J.T. Brandt, and Y.G. Li Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects Pharmacotherapy 28 2008 1483 1494
17. M. Gilard, B. Arnaud, G. Le Gal, J.F. Abgrall, and J. Boschat Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin J Thromb Haemost 4 2006 2508 2509
18. M. Gilard, B. Arnaud, J.C. Cornily, G. Le Gal, K. Lacut, and G. Le Calvez Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
19. D.S. Small, N.A. Farid, C.D. Payne, G.J. Weerakkody, Y.G. Li, and J.T. Brandt Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel J Clin Pharmacol 48 2008 475 484
20. J.M. Siller-Matula, A.O. Spiel, I.M. Lang, G. Kreiner, G. Christ, and B. Jilma Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 2009 148.e1 148.e5
21. M.L. O'Donoghue, E. Braunwald, E.M. Antman, S.A. Murphy, E.R. Bates, and Y. Rozenman Pharmacodynamic effect and clinical efficacy of clopidogrel and plasugrel with or without a proton pump inhibitor: an analysis of two randomized trials Lancet 374 2009 989 997
22. J.S. Hulot, J.P. Collet, J. Silvain, A. Pena, A. Bellemain-Appaix, and O. Barthélémy Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
23. T. Gremmel, S. Steiner, D. Seidinger, R. Koppensteiner, S. Panzer, and C.W. Kopp The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent Thromb Res 128 2011 352 357
24. A. Tsantes, I. Ikonomidis, I. Papadakis, C. Kottaridi, A. Tsante, and E. Kalamara Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance Platelets 23 2012 481 489
25. T. Gremmel, C.W. Kopp, D. Moertl, D. Seidinger, R. Koppensteiner, and S. Panzer Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests Thromb Res 129 2012 616 622
26. L. Bonello, U.S. Tantry, R. Marcucci, R. Blindt, D.J. Angiolillo, and R. Becker Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
27. L. Laine, and C. Hennekens Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction? Am J Gastroenterol 105 2010 34 41
28. T. Cuisset, C. Frere, J. Quilici, R. Poyet, B. Gaborit, and L. Bali Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study J Am Coll Cardiol 54 2009 1149 1153
29. M.L. O'Donoghue, E. Braunwald, E.M. Antman, S.A. Murphy, E.R. Bates, and Y. Rozenman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
30. N.J. Breet, J.W. Van Werkum, H.J. Bouman, J.C. Kelder, H.J.T. Ruven, and E.T. Bal Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
31. A.L. Frelinger III, D.L. Bhatt, R.D. Lee, D.J. Mulford, J. Wu, and S. Nudurupati Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-medications (Including Proton Pump Inhibitors), and Pre-existent Variability in Platelet Function J Am Coll Cardiol 61 2013 872 879
32. A.D. Ferguson, H. Dokainish, and N. Lakkis Aspirin and clopidogrel response variability: review of the published literature Tex Heart Inst J 35 2008 313 320
33. N.F. Ford, and D. Taubert Clopidogrel, CYP2C19, and a Black Box J Clin Pharmacol 53 2013 241 248